^
    Apply
    A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML (NCT03280030)
    Phase 2
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    04/06/2018
    Primary completion :
    11/14/2022
    Completion :
    11/14/2022
    FLT3 • PML
    |
    FLT3 mutation
    |
    cytarabine • midostaurin • daunorubicin
    Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma (NCT05958719)
    Phase 2
    Institute of Hematology & Blood Diseases Hospit...
    Recruiting
    Last update posted :
    12/30/2024
    Initiation :
    03/02/2023
    Primary completion :
    12/30/2026
    Completion :
    03/02/2027
    IFNG • IL6 • TNFA • IL10 • IFNA1
    |
    azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
    Optimum Induction Therapy of Low-risk APL (NCT05832320)
    Phase N/A
    Peking University People's Hospital
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    01/01/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    RARA • PML
    |
    etoposide IV • daunorubicin
    Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (VITAL) (NCT02658487)
    Phase 2
    Vanderbilt-Ingram Cancer Center
    Active, not recruiting
    Last update posted :
    05/03/2024
    Initiation :
    03/01/2016
    Primary completion :
    04/01/2019
    Completion :
    09/01/2024
    SRC
    |
    cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)
    Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML (DaunoDouble) (NCT02140242)
    Phase 3
    Technische Universität Dresden
    Completed
    Last update posted :
    09/15/2023
    Initiation :
    04/16/2014
    Primary completion :
    04/25/2022
    Completion :
    04/25/2022
    NPPB
    |
    daunorubicin
    Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01238211)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/01/2023
    Initiation :
    12/14/2010
    Primary completion :
    07/01/2013
    Completion :
    03/15/2021
    RUNX1 • RUNX1T1
    |
    RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion
    |
    dasatinib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)
    Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia (NCT02914977)
    Phase 1
    Tara Lin
    Completed
    Last update posted :
    01/14/2022
    Initiation :
    11/01/2016
    Primary completion :
    04/03/2019
    Completion :
    07/15/2021
    CTNNB1
    |
    daunorubicin
    Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL) (NCT01191541)
    Phase 4
    Xiaofan Zhu
    Completed
    Last update posted :
    08/10/2021
    Initiation :
    05/01/2010
    Primary completion :
    02/01/2017
    Completion :
    02/01/2017
    RARA
    |
    cytarabine • daunorubicin • arsenic trioxide
    Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia (NCT01627041)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/21/2021
    Initiation :
    09/16/2011
    Primary completion :
    02/11/2016
    RARA • CBFB
    |
    cytarabine • azacitidine • decitabine • daunorubicin • Starasid (cytarabine ocfosfate)
    Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01041703)
    Phase 3
    Eastern Cooperative Oncology Group
    Recruiting
    Last update posted :
    12/08/2017
    Initiation :
    01/01/2011
    Primary completion :
    02/01/2019
    HLA-DRB1
    |
    cytarabine • decitabine • daunorubicin • clofarabine
    Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer (NCT00408603)
    Phase 2
    Sunesis Pharmaceuticals
    Completed
    Last update posted :
    07/27/2017
    Initiation :
    12/20/2006
    Primary completion :
    06/09/2010
    Completion :
    06/09/2010
    MUC16
    |
    cisplatin • Qinprezo (vosaroxin)
    Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients (NCT01889407)
    Phase N/A
    Nanfang Hospital of Southern Medical University
    Unknown status
    Last update posted :
    04/21/2015
    Initiation :
    08/01/2013
    Primary completion :
    07/01/2016
    Completion :
    07/01/2016
    ABCB1 • WT1 • GAPDH
    |
    ABCB1 overexpression
    |
    cytarabine • daunorubicin • idarubicin hydrochloride